Back to Search
Start Over
Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement.
- Source :
-
Hematological oncology [Hematol Oncol] 2022 Oct; Vol. 40 (4), pp. 518-527. Date of Electronic Publication: 2022 Mar 14. - Publication Year :
- 2022
-
Abstract
- The introduction of Bruton's tyrosine kinase (BTK) inhibitors transformed the management of patients with mantle cell lymphoma (MCL). Ibrutinib, the first-in-class BTK inhibitor is now approved in more than 80 countries and there are over 20 new BTK inhibitors in development. In addition, novel agents show potential clinical activity (alone and in combination) and are in the approval phase and/or being studied in ongoing clinical trials. How does the practicing clinician decide on the optimal therapeutic strategy for this highly heterogenous disease? In July 2020 a group of experts from Italy, convened a meeting to address and provide clarification on a series of outstanding issues in the treatment of MCL with the view of providing clinical guidance on its management. This expert opinion statement represents the panel's collective analysis, evaluation, and recommendations and is made up of a series of questions and answers (in the form of a review of the pertinent literature) designed to replicate those posed by practicing clinicians in Italy but which are applicable to clinical settings worldwide.<br /> (© 2022 John Wiley & Sons Ltd.)
- Subjects :
- Adenine analogs & derivatives
Adult
Agammaglobulinaemia Tyrosine Kinase antagonists & inhibitors
Humans
Piperidines
Antineoplastic Agents therapeutic use
Lymphoma, Mantle-Cell drug therapy
Lymphoma, Mantle-Cell pathology
Protein Kinase Inhibitors pharmacology
Protein Kinase Inhibitors therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1099-1069
- Volume :
- 40
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Hematological oncology
- Publication Type :
- Academic Journal
- Accession number :
- 35247223
- Full Text :
- https://doi.org/10.1002/hon.2983